Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilles Devouassoux

Showing results (51-60 of 86) with videos related to

Pageof 9
Sort By:
American Journal of Respiratory and Critical Care Medicine|June 24, 2026
Reply to Siddiqui et al., Godbout et al., and to Chang and MaoGeoffrey Chupp, Hiroyuki Nagase, Dirk Skowasch, et al.
The European Respiratory Journal|April 4, 2020
Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programmeCamille Taillé, Pascal Chanez, Gilles Devouassoux, et al.
Journal of Fungi (Basel, Switzerland)|June 27, 2023
Characterization of Lung Inflammatory Response to <i>Aspergillus fumigatus</i> SporesAlexandra Bouyssi, Tanguy Déméautis, Alexis Trecourt, et al.
The Lancet. Respiratory Medicine|January 28, 2014
Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group studyMarc L Decramer, Kenneth R Chapman, Ronald Dahl, et al.
The Journal of Allergy and Clinical Immunology|June 7, 2024
Anti-IL-4R versus anti-IL-5/5R after anti-IL-5/5R failure in asthma: An emulated target trialSolène Valery, Noémie Simon-Tillaux, Gilles Devouassoux, et al.
Allergy|May 4, 2019
The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthmaKenneth R Chapman, Frank C Albers, Bradley Chipps, et al.
Therapeutic Advances in Respiratory Disease|October 11, 2021
Anti-interleukin 5 therapies failure criteria in severe asthma: a Delphi-consensus studyLaura Mattei, Carey M Suehs, Khuder Alagha, et al.
Respiratory Medicine and Research|February 1, 2023
Eligibility to lung cancer screening among staffs of a university hospital: A large cross-sectional surveyEmmanuel Grolleau, Julie de Bermont, Flavien Devun, et al.
ACS Omega|June 21, 2021
Magnetic Resonance Imaging of Protease-Mediated Lung Tissue Inflammation and InjuryAngélique Rivot, Natacha Jugniot, Samuel Jacoutot, et al.
Respiratory Research|May 11, 2021
Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristicsMark C Liu, Bradley Chipps, Xavier Munoz, et al.
Pageof 9

Showing results (51-60 of 86) with videos related to

Sort By:
Pageof 9
American Journal of Respiratory and Critical Care Medicine|June 24, 2026
Reply to Siddiqui et al., Godbout et al., and to Chang and MaoGeoffrey Chupp, Hiroyuki Nagase, Dirk Skowasch, et al.
The European Respiratory Journal|April 4, 2020
Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programmeCamille Taillé, Pascal Chanez, Gilles Devouassoux, et al.
Journal of Fungi (Basel, Switzerland)|June 27, 2023
Characterization of Lung Inflammatory Response to <i>Aspergillus fumigatus</i> SporesAlexandra Bouyssi, Tanguy Déméautis, Alexis Trecourt, et al.
The Lancet. Respiratory Medicine|January 28, 2014
Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group studyMarc L Decramer, Kenneth R Chapman, Ronald Dahl, et al.
The Journal of Allergy and Clinical Immunology|June 7, 2024
Anti-IL-4R versus anti-IL-5/5R after anti-IL-5/5R failure in asthma: An emulated target trialSolène Valery, Noémie Simon-Tillaux, Gilles Devouassoux, et al.
Allergy|May 4, 2019
The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthmaKenneth R Chapman, Frank C Albers, Bradley Chipps, et al.
Therapeutic Advances in Respiratory Disease|October 11, 2021
Anti-interleukin 5 therapies failure criteria in severe asthma: a Delphi-consensus studyLaura Mattei, Carey M Suehs, Khuder Alagha, et al.
Respiratory Medicine and Research|February 1, 2023
Eligibility to lung cancer screening among staffs of a university hospital: A large cross-sectional surveyEmmanuel Grolleau, Julie de Bermont, Flavien Devun, et al.
ACS Omega|June 21, 2021
Magnetic Resonance Imaging of Protease-Mediated Lung Tissue Inflammation and InjuryAngélique Rivot, Natacha Jugniot, Samuel Jacoutot, et al.
Respiratory Research|May 11, 2021
Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristicsMark C Liu, Bradley Chipps, Xavier Munoz, et al.
Pageof 9